CSPC Pharmaceutical (HKG:1093) obtained approval to conduct a clinical trial of its SYH2046 tablets in China from the country's National Medical Products Administration, a Friday filing with the Hong Kong bourse said.
The indication for the trial approval is heart failure after acute myocardial infarction.
Preclinical studies have shown the drug to improve cardiac function and reduce adverse cardiac remodeling in disease animal models with a better safety profile.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.